海正生材: 浙江海正生物材料股份有限公司第七届董事会第十七次会议决议公告

Core Viewpoint - The board of directors of Zhejiang Haizheng Biological Materials Co., Ltd. held its 17th meeting of the 7th session, where several key resolutions were passed, including the approval of the 2025 semi-annual report and adjustments to the share repurchase plan [1][2][3] Group 1: Semi-Annual Report - The board approved the 2025 semi-annual report and its summary, which was reviewed by the audit committee [1] - The voting results for this resolution were unanimous, with 9 votes in favor and no opposition or abstentions [1] Group 2: Fund Usage Report - The board approved a special report on the storage and usage of funds raised in the first half of the year [2] - This resolution also received unanimous support, with 9 votes in favor [2] Group 3: Quality Improvement Action Plan - The board approved a semi-annual evaluation report on the quality improvement and efficiency enhancement action plan for 2025 [2] - The voting results were again unanimous, with 9 votes in favor [2] Group 4: Election of Executive Director - The board elected Chairman Zheng Baichao as the representative director to execute company affairs, confirming no change in the legal representative of the company [2][3] - This resolution was passed with unanimous support, receiving 9 votes in favor [3] Group 5: Audit Committee Confirmation - The board confirmed the members and convener of the audit committee, which includes professionals with accounting expertise [3] - The voting results were unanimous, with 9 votes in favor [3] Group 6: Share Repurchase Plan Adjustment - The board approved an adjustment to the maximum repurchase price from 12 CNY per share to 17 CNY per share and extended the implementation period by 6 months, now ending on February 27, 2026 [3] - This resolution also received unanimous support, with 9 votes in favor [3]